SCHEMBL6723536

SCHEMBL6723536

N#Cc1cccc(-c2noc(CF)c2-c2ccc(S(N)(=O)=O)c(F)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.51
PTGES2 Q9H7Z7 2/20 0.37
PTGS1 P23219 2/20 0.36
NR3C2 P08235 1/20 0.36
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 1/20 0.35
CA13 Q8N1Q1 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
ADORA2B P29275 2/20 0.34
ADORA2A P29274 2/20 0.33
ADORA1 P30542 2/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA5 P30532 1/20 0.33
CHRNA4 P43681 1/20 0.33
ACLY P53396 1/20 0.33
CA4 P22748 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6721416 0.91 PTGS2 (0.50) PTGS2PTGES2PTGS1NR3C2CA1
SCHEMBL6722875 0.90 PTGS2 (0.43) PTGS2NR3C2GABRG2GABRB3GABRA5
SCHEMBL6730494 0.90 PTGS2 (0.52) PTGS2PTGES2PTGS1CA1CA2
SCHEMBL6736291 0.88 PTGS2 (0.50) PTGS2PTGES2NR3C2CA1CA2
SCHEMBL6733968 0.87 PTGS2 (0.45) PTGS2PTGES2NR3C2CA1CA2
SCHEMBL6730505 0.87 PTGS2 (0.56) PTGS2PTGS1CA1CA2CA9
SCHEMBL6725852 0.86 PTGS2 (0.47) PTGS2PTGES2PTGS1NR3C2CA1
SCHEMBL6725847 0.85 PTGS2 (0.69) PTGS2PTGS1CA1CA2CA9
SCHEMBL6723174 0.85 PTGS2 (0.54) PTGS2PTGS1CA1CA2CA9
SCHEMBL6722666 0.85 PTGS2 (0.54) PTGS2PTGS1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885PTGES2 3/4885PTGS1 4/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885PTGES2 2/4885PTGS1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.